$0.844
+0.017 (+2.07%)收盘时
- High
- 0.861
- Open
- 0.803
- VWAP
- 0.81
- Vol
- 5.25M
- Mkt Cap
- 10.20M
- Low
- 0.739
- Amount
- 4.28M
- EV/EBITDA, TTM
- 0.00
Mainz Biomed N.V. is a Germany based molecular genetics cancer diagnostic company. The Company operates under one segment, namely genetic diagnostic testing services. Its portfolio consists of various products and product candidates, such as ColoAlert, a colorectal cancer (CRC) screening stool-based DNA (deoxyribonucleic acid) test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, a platform technology to detect pathogens in environments on a molecular genetic basis. The Company competes with Exact Sciences, Epigenomics AG, Novigenix SA, GRAIL, Inc. and Agena Biosciences Inc.
AI analysis of Mainz Biomed NV (MYNZ)
holdMainz Biomed NV (MYNZ) is not a strong buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock lacks positive trading signals, has no significant news or catalysts, and faces uncertainties due to a shift in business strategy and dilution concerns. It is better to hold off on investing in this stock at this time.
估值指标
事件时间线
资讯
8.502-24NewsfilterMainz Biomed to Present at Digestive Disease Week 2026
8.502-17seekingalphaMainz Biomed Secures $6 Million Financing for Strategic Shift
- 8.502-17Newsfilter
Mainz Biomed Secures $6 Million Funding to Enhance Liquidity and Focus on Pancreatic Cancer Detection
2.001-05GlobenewswireMainz Biomed Launches eAArly DETECT 2 Clinical Study Covering 2,000 Patients
7.512-02GlobenewswireMainz Biomed Integrates ColoAlert® Test into DoctorBox Platform in Germany
MYNZ FAQ — answered by Alphio AI
Mainz Biomed N.V. is a Germany based molecular genetics cancer diagnostic company. The Company operates under one segment, namely genetic diagnostic testing services. Its portfolio consists of various products and product candidates, such as ColoAlert, a colorectal cancer (CRC) screening stool-based DNA (deoxyribonucleic acid) test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, a platform technology to detect pathogens in environments on a molecular genetic basis. The Company competes with Exact Sciences, Epigenomics AG, Novigenix SA, GRAIL, Inc. and Agena Biosciences Inc. It operates in the Healthcare sector.
Mainz Biomed NV (MYNZ) is not a strong buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock lacks positive trading signals, has no significant news or catalysts, and faces uncertainties due to a shift in business strategy and dilution concerns. It is better to hold off on investing in this stock at this time.
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。